Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Nod For Selincro May Give Lundbeck Much Needed Revenue Boost

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE's positive recommendation for Lundbeck's Selincro for alcohol dependence should give the Danish biotech a revenue boost and help offset expiry of its Lexapro/Cipralex patent.

You may also be interested in...



Many New Products For Forest, But Not Enough To Fill The Lexapro Gap

The launches of Tudorza for COPD and Linzess for irritable bowel syndrome are off to strong starts, Forest executives said during the company’s fiscal fourth quarter sales and earnings call. But despite those and other recent entries, the company reported a net loss for the year after revenues nose-dived from the loss of Lexapro.

EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum

Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).

Finland's Biotie Therapies Renegotiates Nalmefene Deal And Receives €30 Million Funding Lifeline

With the end of its cash runway on the horizon, Finland’s Biotie Therapies has received an equity investment of €10 million from Lundbeck and €20 million from institutional investors, after renegotiating the ex-Europe part of its worldwide nalmefene licensing pact.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077421

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel